Logo

ArriVent BioPharma Collaborates with Alphamab to Develop Antibody Drug Conjugates for Treating Cancers

Share this
ArriVent BioPharma

ArriVent BioPharma Collaborates with Alphamab to Develop Antibody Drug Conjugates for Treating Cancers

Shots:

  • ArriVent and Jiangsu Alphamab Biopharmaceuticals have signed a collaboration agreement for the discovery, development & commercialization of new ADCs for cancer treatment
  • As per the agreement, the companies will identify ADCs using Alphamab’s linker-payload platform and glycan-conjugation technology. ArriVent gains exclusive worldwide (excl. greater China) rights for its development & commercialization while Alphamab keeps the rights across greater China (outside of mainland China, Hong Kong, Macau & Taiwan)
  • Furthermore, Alphamab will receive a total of up to $615.5M incl. upfront as well as regulatory, development & sales milestones for the programs plus tiered sales-based royalties for every ADC

Ref: ArriVent Image: ArriVent

Related News:- InnoCare Entered into a Clinical Development Collaboration with ArriVent to Evaluate ICP-189 + Furmonertinib for Advanced Non-Small Cell Lung Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions